Aviram M
Lipid Research Laboratory, Rambam Medical Center, Rappaport Family Institute for Research in the Medical Sciences, Technion Faculty of Medicine, Haifa, Israel.
Biochem Biophys Res Commun. 1991 Aug 30;179(1):359-65. doi: 10.1016/0006-291x(91)91378-p.
Oxidized LDL (Ox-LDL) was shown to be taken up by macrophages via several receptors including the acetyl-LDL(Ac-LDL), the LDL, and the Ox-LDL receptors. Cellular uptake and degradation of Ox-LDL could be dissociated from that of LDL and Ac-LDL as demonstrated by using macrophages that lack the LDL or the Ac-LDL receptors. In J-774 A.1 macrophage-like cell line unlabeled Ox-LDL reduced the 125I-Ox-LDL by up to degradation of 91% whereas unlabeled Ac-LDL and native LDL reduced 125I-Ox-LDL degradation by only 51% and 23%, respectively. Analysis of macrophage degradation of 125I-Ox-LDL in the presence of 30-fold excess concentration of LDL + Ac-LDL (to block uptake of 125I-Ox-LDL via the LDL and the Ac-LDL receptors) revealed that cellular degradation via the Ox-LDL receptor could account for 45% of the macrophage uptake of Ox-LDL.
氧化型低密度脂蛋白（Ox-LDL）已被证明可通过几种受体被巨噬细胞摄取，这些受体包括乙酰化低密度脂蛋白（Ac-LDL）、低密度脂蛋白（LDL）和氧化型低密度脂蛋白受体。如使用缺乏低密度脂蛋白或乙酰化低密度脂蛋白受体的巨噬细胞所证明的那样，氧化型低密度脂蛋白的细胞摄取和降解与低密度脂蛋白和乙酰化低密度脂蛋白的摄取和降解是可分离的。在J-774 A.1巨噬细胞样细胞系中，未标记的氧化型低密度脂蛋白可使125I-氧化型低密度脂蛋白的降解率高达91%，而未标记的乙酰化低密度脂蛋白和天然低密度脂蛋白分别仅使125I-氧化型低密度脂蛋白的降解率降低51%和23%。在存在30倍过量浓度的低密度脂蛋白+乙酰化低密度脂蛋白（以阻断125I-氧化型低密度脂蛋白通过低密度脂蛋白和乙酰化低密度脂蛋白受体的摄取）的情况下，对巨噬细胞降解125I-氧化型低密度脂蛋白的分析表明，通过氧化型低密度脂蛋白受体的细胞降解可占巨噬细胞摄取氧化型低密度脂蛋白的45%。
